Icis Treatment for Different MSI Colorectal Cancer: Theoretical Basis, Status Quo And Outlook
DOI:
https://doi.org/10.54097/cfah0596Keywords:
Colorectal cancer (CRC), immune checkpoint inhibitors (ICIs), microsatellite instability (MSI), drug resistance.Abstract
As the third cancer worldwide, the incidence and the cancer-related mortality is both high in colorectal cancer (CRC) patients. The treatment of CRC has standard methods, including radiotherapy, chemotherapy and other general therapy. However, these systemic therapies are not specific, which are also toxic for normal cells and show many side effects in patients. New immunotherapeutic strategies have changed the landscape of treatment of metastatic CRC (mCRC), especially immune checkpoint inhibitors (ICIs). After research, the condition of microsatellite instability (MSI) has proven to be one of the main influencing factors of ICIs' efficacy. This review comprehensively analyses the possible mechanisms underlying the varying efficacy of ICIs in the treatment of different MSI tumors and evaluates potential therapeutic strategies that offer possible ways to overcome resistance mechanisms.
Downloads
References
Shan J, Han D, Shen C, Lei Q, Zhang Y. Mechanism and strategies of immunotherapy resistance in colorectal cancer. Front Immunol, 2022,13:1016646.
Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, Diaz LA Jr. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol, 2019,16(6):361-375.
Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol, 2020,20(11):651-668.
Luchini C, Bibeau F, Ligtenberg MJL, Singh N, Nottegar A, Bosse T, Miller R, Riaz N, Douillard JY, Andre F, Scarpa A. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol, 2019,30(8):1232-1243.
Yu H, Aihua L, Rong L. Immunogenic cell death inducers and their anti-tumor applications, Chemistry of Life,2021,41(11):2411-2416.
Kanaya N, Kuroda S, Kakiuchi Y, et al. Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody. Mol Ther. 2020 Mar 4;28(3):794-804.
Xuqiang L. Analysis of Clinical Efficacy and Safety of Immune Checkpoint Inhibitors Plus Anti-Angiogenic Agents in Common Malignant Tumors. Nanchang University, 2023, MA thesis.
Fukuoka S, Hara H, Takahashi N, et al. Regorafenib Plus Nivolumab in Patients with Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). J Clin Oncol, 2020, 38(18):2053-2061.
Xiaojing Q, Xue L, Wen-xin L. T cell redirection bispecific antibodies in tumour therapy challenges and strategies. China Biotechnology, 2023,43(06):31-42.
Wunderlich M, Manning N, Sexton C, et al. PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of Relapsed Pediatric B-Cell Acute Lymphoblastic Leukemia. Front Oncol, 2021,11:642466.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
